FORESITE CAPITAL MANAGEMENT V LLC
Q2 2022 Form 13-F

LARKSPUR, CALIFORNIA
CIK 0001792206 · CRD 162823 · SEC-registered investment adviser
$143.1M Reported Value Total

FORESITE CAPITAL reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $3,907,345,201, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
24 funds · $3.4B gross asset value
Venture Capital Fund: $3.4B · Private Equity Fund: $55.4M
Source: Form ADV filed 2026-10-20
Reported value
$143.1M
Quarter over quarter
-36.4%
Holdings
14
Top-10 concentration
95.9%

Key People

Form ADV owners & control persons
Amelia Buckley Stoj
CHIEF COMPLIANCE OFFICER AND ASSISTANT GENERAL COUNSEL
Dana Shonfeld Tananbaum
TRUSTEE
James Bruce Tananbaum
MANAGER, CEO, TRUSTEE

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2022 13F record

Q2 2022 13F filing summary

Q2 2022 Form 13F portfolio summary
Period of report June 30, 2022
Filed August 12, 2022
Form 13F-HR
Reported value $143.1M
Positions 14
Change in reported value -41.6%
New positions 0
Exited positions 3
Position turnover 17.7%
Top-10 concentration 95.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
9 $289.1M
Q2 2026 13F
Filed Aug 14, 2026
9 $362.2M
Q1 2026 13F
Filed May 15, 2026
9 $271.0M
Q4 2025 13F
Filed Feb 17, 2026
7 $164.4M
Q3 2025 13F
Filed Nov 14, 2025
6 $108.7M
Q2 2025 13F
Filed Aug 12, 2025
6 $80.7M
Q1 2025 13F
Filed May 15, 2025
6 $87.6M
Q4 2024 13F
Filed Feb 14, 2025
6 $120.2M
Q3 2024 13F
Filed Nov 14, 2024
5 $143.9M
Q2 2024 13F
Filed Aug 13, 2024
5 $156.6M
Q1 2024 13F
Filed May 15, 2024
5 $106.5M
Q4 2023 13F
Filed Feb 13, 2024
5 $73.4M
Q3 2023 13F
Filed Nov 13, 2023
7 $62.7M
Q2 2023 13F
Filed Aug 11, 2023
10 $136.9M
Q1 2023 13F
Filed May 12, 2023
11 $135.3M
Q4 2022 13F
Filed Feb 13, 2023
11 $128.8M
Q3 2022 13F
Filed Nov 14, 2022
14 $130.1M
Q2 2022 13F
Filed Aug 12, 2022
14 $143.1M
Q1 2022 13F
Filed May 13, 2022
17 $244.9M
Q4 2021 13F
Filed Feb 11, 2022
16 $407.0M

4 earlier quarters on file — choose one from the quarter menu above.

Top 14 holdings · Q2 2022

Largest Q2 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 PRDS Pardes Biosciences Inc $28.9M 20.16%
2 THRX Theseus Pharmaceuticals, Inc. $18.4M 12.89%
3 ACRS Aclaris Therapeutics, Inc. $17.6M 12.27%
4 SLGC Somalogic, Inc. $15.9M 11.1%
5 HIMS Hims & Hers Health, Inc. $15.0M 10.51%
6 CMPX Compass Therapeutics, Inc. $11.7M 8.15%
7 KNTE Kinnate Biopharma Inc. $11.0M 7.71%
8 ACET Adicet Bio, Inc. $9.9M 6.94%
9 IVVD Adagio Therapeutics, Inc. $4.7M 3.28%
10 GMTX Gemini Therapeutics, Inc. $4.1M 2.87%
11 QSI Quantum-Si Incorporated $2.1M 1.5%
12 ENTA Enanta Pharmaceuticals, Inc. $2.0M 1.4%
13 ME 23andMe Holding Co. $1.0M 0.7%
14 PHVS Pharvaris N.V. $755.0K 0.53%

Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings